An electro-stimulation device includes a pair of electrodes for connection to at least one location in the body that affects or regulates the heartbeat. The electro-stimulation device both electrically arrests the heartbeat and stimulates the heartbeat. A pair of electrodes are provided for connection to at least one location in the body that affects or regulates the heartbeat. The pair of electrodes may be connected to an intravenous catheter for transvenous stimulation of the appropriate nerve. A first switch is connected between a power supply and the electrodes for selectively supplying current from the power supply to the electrodes to augment any natural stimuli to the heart and thereby stop the heart from beating. A second switch is connected between the power supply and the electrodes for selectively supplying current from the power supply to the electrodes to provide an artificial stimulus to initiate heartbeating. In another aspect, the invention is directed to a method for arresting the beat of a heart in a living body comprising the steps of connecting the pair of electrodes to at least one location in the body that affects or regulates the heartbeat and supplying an electrical current to the electrodes of sufficient amplitude and duration to arrest the heartbeat. The device may also serve to still the lungs by input to a respirator or by stimulation of the phrenic nerve during surgical procedures.

Patent
   RE38654
Priority
Apr 30 1996
Filed
Nov 15 2001
Issued
Nov 23 2004
Expiry
Apr 30 2016
Assg.orig
Entity
Large
155
21
all paid
0. 118. A method for selectively supplying electricity to at least one location within a patient during a medical procedure comprising:
a. connecting a first set of at least two electrodes to at least one first location within the patient, at least one of the electrodes being placed within a blood vessel adjacent a nerve fiber that regulates an organ within the patient;
b. connecting a second set of at least two electrodes to at least one second location within the patient that regulates the organ;
c. supplying electrical energy from a power supply to at least one set of electrodes, the supply of the electrical energy to the electrodes being of sufficient amplitude and duration to stimulate or destimulate the organ.
119. A method for selectively supplying electricity to at least one location within a patient during a surgical procedure comprising:
a. connecting a first set of at least two electrodes to at least one first location within the patient that regulates an organ within the patient;
b. connecting a second set of at least two electrodes to at least one second location within the patient that regulates the organ;
c. selectively supplying energy from the power supply to the first set of electrodes during the surgical procedure, the supply of the electrical energy to the first set of electrodes being of sufficient amplitude and duration to destimulate the organ, thereby slowing or arresting movement of the organ;
d. selectively supplying energy from the power supply to the second set of electrodes during the surgical procedure, the supply of the electrical energy to the second set of electrodes being of sufficient amplitude and duration to stimulate the organ.
1. A device for selectively supplying electrical energy to at least one location within a patient during a medical procedure comprising:
a. a power supply for supplying electrical energy;
b. a first set of at least two electrodes for connection to at least one first location within the patient that regulates an organ within the patient;
c. a first switch, the first switch being connected between the power supply and the first set of electrodes, the first switch controlling the supply of the electrical energy from the power supply to the first set of electrodes, the supply of the electrical energy supplied to the electrodes being of sufficient amplitude or duration to destimulate the organ, thereby slowing or arresting movement of the organ;
d. a second set of at least two electrodes for connection to at least one second location within the patient that regulates the organ; and
e. a second switch, the second switch being connected between the power supply and the second set of electrodes, the second switch controlling the supply of the electrical energy from the power supply to the second set of electrodes, the supply of the electrical energy being of sufficient amplitude or duration to stimulate the organ.
2. The device of claim 1 wherein the first set of electrodes are adapted to be coupled to the patient's heart.
3. The device of claim 1 wherein the first set of electrodes are adapted to be coupled to the patient's lung.
4. The device of claim 1 wherein the first set of electrodes are adapted to be coupled to the patient's stomach.
5. The device of claim 1 wherein the first set of electrodes are adapted to be coupled to the patient's muscle.
6. The device of claim 1 wherein the first set of electrodes are adapted to be coupled to the patient's spinal cord.
7. The device of claim 1 wherein the first set of electrodes are adapted to be coupled to the patient's nerve fiber.
8. The device of claim 7 wherein the nerve fiber is a vagal nerve fiber.
9. The device of claim 7 wherein the nerve fiber is a parasympathetic nerve fiber.
10. The device of claim 7 wherein the nerve fiber is a sympathetic nerve fiber.
11. The device of claim 7 wherein the nerve fiber is a hypoglossal nerve fiber.
12. The device of claim 7 wherein the nerve fiber is a phrenic nerve fiber.
13. The device of claim 7 wherein the first set of electrodes are adapted to be coupled to the patient via placement of at least one electrode in a blood vessel adjacent a nerve fiber.
14. The device of claim 13 wherein the blood vessel is an artery.
15. The device of claim 13 wherein the blood vessel is a vein.
16. The device of claim 13 wherein the blood vessel is a jugular vein.
17. The device of claim 13 wherein the blood vessel is a superior vena cava.
18. The device of claim 13 wherein the blood vessel is a azygous vein.
19. The device of claim 13 wherein the blood vessel is a hemizygous vein.
20. The device of claim 7 wherein the nerve fiber is located in an epicardial fat pad.
21. The device of claim 20 wherein the epicardial fat pad is located at the right atrium.
22. The device of claim 20 wherein the epicardial fat pad is located at the superior vena cava.
23. The device of claim 20 wherein the epicardial fat pad is located at the right pulmonary vein.
24. The device of claim 1 wherein at least one location is at least one point located on a nerve fiber.
25. The device of claim 1 wherein at least one location is at least one point located on an organ wall.
26. The device of claim 1 wherein at least one location is at least one point located adjacent a nerve fiber.
27. The device of claim 1 wherein the electrical energy is an alternating energy.
28. The device of claim 1 wherein the electrical energy is a waveform energy.
29. The device of claim 1 wherein the electrical energy is a direct energy.
30. The device of claim 29 wherein the direct energy is a pulsed energy.
31. The device of claim 1 wherein the electrical energy is a continuous pulse train of about 10 to 30 seconds.
32. The device of claim 1 wherein the electrical energy is a constant energy of about 10 to 100 milliamps.
33. The device of claim 1 wherein the electrical energy is a constant pulse width of about 0.01 to 0.5 milliseconds.
34. The device of claim 1 wherein the electrical energy comprises a frequency between about 6 and 50 hertz.
35. The device of claim 1 wherein the electrical energy comprises a burst pulse width of energy.
36. The device of claim 35 wherein the burst pulse width of energy is programmably controlled.
37. The device of claim 1 wherein the power supply is a regulated power source.
38. The device of claim 1 wherein the power supply comprises a battery and a regulator.
39. The device of claim 1 wherein the device is an implantable pacemaker.
40. The device of claim 1 wherein the device is an external pacemaker.
41. The device of claim 1 wherein the device is a cardiac pacemaker.
42. The device of claim 1 wherein the device is a diaphragmatic pacemaker.
43. The device of claim 1 wherein the device is an implantable nerve stimulator.
44. The device of claim 1 wherein the device is a external nerve stimulator.
45. The device of claim 1 wherein the first set of electrodes are located bilaterally.
46. The device of claim 1 wherein the second set of electrodes are located bilaterally.
47. The device of claim 1 wherein at least one set of electrodes further comprise a nerve cuff electrode.
48. The device of claim 1 wherein at least one set of electrodes are implantable electrodes.
49. The device of claim 1 wherein at least one set of electrodes are attached to a transvenous lead.
50. The device of claim 1 wherein at least one set of electrodes are attached to an electrode pad.
51. The device of claim 1 wherein at least one set of electrodes are attached to an intravenous catheter.
52. The device of claim 51 wherein the electrodes are positioned circumferentially around the catheter.
53. The device of claim 51 wherein the electrodes are positioned axially along the catheter.
54. The device of claim 51 wherein the electrodes are positioned both axially along the catheter and circumferentially around the catheter.
55. The device of claim 1 wherein the electrodes are used for sensing.
56. The device of claim 1 wherein at least one electrode is connected to a sinoatrial region of a heart.
57. The device of claim 1 wherein at least one electrode is connected to an atrioventricular region of the heart.
58. The device of claim 1 wherein at least one set of electrodes are connected in a unipolar arrangement.
59. The device of claim 1 wherein at least one set of electrodes are connected in a bipolar arrangement.
60. The device of claim 1 wherein at least one electrode comprises a corkscrew.
61. The device of claim 1 wherein at least one electrode comprises a clip.
62. The device of claim 1 wherein at least one electrode comprises a pad.
63. The device of claim 1 wherein at least one electrode comprises a tine.
64. The device of claim 1 wherein at least one electrode comprises a barb.
65. The device of claim 1 wherein at least one electrode comprises a needle.
66. The device of claim 1 wherein at least one set of electrodes are controlled by a sensor.
67. The device of claim 1 wherein at least one electrode comprises a lead.
68. The device of claim 1 wherein at least one set of electrodes comprise an electrode array.
69. The device of claim 1 wherein the medical procedure is a diagnostic procedure.
70. The device of claim 1 wherein the medical procedure is a therapeutic procedure.
71. The device of claim 1 wherein the medical procedure is a minimally invasive surgical procedure.
72. The device of claim 1 wherein the medical procedure is an open heart surgical procedure.
73. The device of claim 1 wherein the medical procedure is a coronary artery bypass graft surgical procedure.
74. The device of claim 1 wherein the medical procedure is a laproscopic surgical procedure.
75. The device of claim 1 wherein the medical procedure is a endoscopicsurgical procedure.
76. The device of claim 1 wherein the medical procedure is a minithorascopic surgical procedure.
77. The device of claim 1 wherein the medical procedure treats arrhythmias.
78. The device of claim 1 wherein the medical procedure treats angina.
79. The device of claim 1 wherein the medical procedure treats ischemia.
80. The device of claim 1 wherein the medical procedure treats obstructive sleep apnea.
81. The device of claim 1 wherein the medical procedure controls breathing.
82. The device of claim 1 wherein at least one switch is operated manually.
83. The device of claim 1 wherein at least one switch is operated automatically.
84. The device of claim 1 wherein at least one switch is a hand switch.
85. The device of claim 1 wherein at least one switch is a foot switch.
86. The device of claim 1 wherein at least one switch is controlled by a timer.
87. The device of claim 1 wherein at least one switch intermittently changes between stimulation and destimulation each time the switch is actuated.
88. The device of claim 1 wherein the device further comprises a timer that sets off an audible signal to indicate when the selected amount of time has been reached.
89. The device of claim 1 wherein the device further comprises a stimulation timer circuit.
90. The device of claim 1 wherein the device further comprises a destimulation timer circuit.
91. The device of claim 1 wherein the device further comprises a stimulation power amplifier.
92. The device of claim 1 wherein the device further comprises a destimulation power amplifier.
93. The device of claim 1 wherein the device further comprises a drug dispenser connected to the power supply.
94. The device of claim 1 wherein the device further comprises a muscle stimulator connected to the power supply.
95. The device of claim 1 wherein the device comprises a nerve stimulation monitoring system connected to the power supply.
96. The device of claim 1 wherein the device further comprises a sensor connected to the power supply.
97. The device of claim 96 wherein the sensor regulates at least one pair of electrodes.
98. The device of claim 96 wherein the sensor is an electrical sensor.
99. The device of claim 96 wherein the sensor is a pressure sensor.
100. The device of claim 96 wherein the sensor is a temperature sensor.
101. The device of claim 1 further comprising:
a. a housing, the housing being connected to the power supply; and
b. a control panel, the control panel being located on the surface of the housing.
102. The device of claim 101 wherein the housing comprises at least one display.
103. The device of claim 101 wherein the housing comprises a microprocessor.
104. The device of claim 101 wherein the control panel comprises a plurality of keys.
105. The device of claim 101 wherein the control panel comprises a heart stimulation control area.
106. The device of claim 101 wherein the control panel comprises a heart destimulation control area.
107. The device of claim 101 wherein the control panel comprises a diaphragm stimulation control area.
108. The device of claim wherein the control panel comprises at least one rotary dial.
109. The device of claim 101 wherein the control panel comprises at least one scale.
110. The device of claim 101 wherein the control panel comprises a means for regulating the pulse width of the electrical energy.
111. The device of claim 101 wherein the control panel comprises a means for regulating the pulse voltage of the electrical energy.
112. The device of claim 101 wherein the control panel comprises a means for regulating the pulse phases of the electrical energy.
113. The device of claim 101 wherein the control panel comprises a means for regulating the burst duration of the electrical energy.
114. The device of claim 101 wherein the control panel comprises an on/off switch for turning the entire device on or off.
115. The device of claim 1 further comprising a foot switch through which the first and the second switch may be actuated.
116. The device of claim 1 further comprising a third set of at least two electrodes connected to the power supply, the third set of electrodes for connection to at least one point located on or adjacent a phrenic nerve fiber of the patient, the third set of electrodes supplying the electrical energy from the power supply to the phrenic nerve fiber upon stimulation or destimulation of the organ, the supply of the electrical energy being of sufficient amplitude and duration to control the patient's breathing.
117. The device of claim 1 further comprising an electrical lead connected to the power supply having a connector that interfaces with a respirator and upon stimulation or destimulation of the organ supplies a signal to the respirator to activate or deactivate the respirator.

This application is a continuation of U.S. Ser. No. 09/070,506 filed Apr. 30, 1998, now U.S. Pat. No. 6,006,134

Referring now to FIG. 1, a first embodiment of an electro-stimulation device 10 includes a housing 12 and a control panel 14 located on an upper surface of the housing 12 The control panel 14 is divided into a heart stimulation control area 15 and a heart destimulation control area 17. The stimulation control area 15 includes a rotary dial 16 and scale 16A for setting the amount of current that is passed to the heart, and a rotary dial 18 and scale 18A for setting the duration or frequency of cycles that the current is passed to the heart to start the heart beating. Likewise, the destimulation control area 17 includes a rotary dial 20 and scale 20A for setting the amount of current that is passed to the heart, and a rotary dial 22 and scale 22A for setting the duration that the current is passed to the heart to stop the heart from beating. Controls for regulating pulse width, pulse voltage, pulse phases and/or burst duration may also be added. A normally open stimulation switch 24 can be pressed to initiate heart stimulation while a normally open destimulation switch 26 can be pressed to initiate the heart destimulation. An on/off switch 28 can be used to turn the entire device off when not in use.

A foot pedal assembly 30 has a normally open heart stimulation foot switch 32 and a heart destimulation foot switch 34 that can be used as an alternative to switches 24, 26. The provision of a foot pedal assembly permits the surgeon to control when the heart stimulation and destimulation occurs while leaving the hands free to perform other procedures. This also permits the surgeon's hands to remain sterile since contact with the housing 12 or switches 26, 28 is avoided. The foot pedal assembly 30 is connected via cable 36 to an electronic control device 50 (FIG. 3) within the housing 12. An alternative to providing two different foot switches 32, 34 would be to provide a single foot switch which intermittently switches between stimulation and destimulation each time the switch is actuated. It is also contemplated that automatic stimulation could be provided after a preset time period or only if the device detects that the heart did not automatically restart.

A pair of electrodes 37, 38 are connected via a pair of leads 39A, 39B, respectively, to the electronic control device 50 for supplying electrical current to the heart during stimulation and destimulation. A second pair of electrodes 43A, 45A can also be connected via a pair of leads 43, 45, respectively, to the electronic control device 50 for supplying electrical current to the phrenic nerve to control breathing during heart stimulation and destimulation. A lead 48 having a connector 49 may be provided in addition to or alternatively of the phrenic nerve electrodes 43A, 43B. The connector 49 interfaces with a respirator (not shown) and, upon stimulation or destimulation of the heart, sends a logic signal to activate or deactivate the respirator.

Referring now to FIG. 2, a second embodiment of an electro-stimulation device 40 according to a second embodiment is shown, wherein like parts from the previous embodiment are represented by like numerals. The electro-stimulation device 40 is microprocessor based and includes a housing 41 having a display 42, a plurality of numeric keys 44, a heart stimulation switch 46, and a heart destimulation switch 48. One of the keys 44 may be an on/off switch for supplying electrical power to the device 40. The device 40 prompts a user to enter the patient's age, height, weight, body temperature, etc., via the keys 44 to calculate the proper amount of electrical current and its duration necessary for proper heart stimulation and destimulation. In most instances, the amount of current and duration to stop the heart will typically be different than the amount of current and duration to start the heart, and will vary from one person to another depending on factors such as height, weight, body temperature, etc. In the embodiments of FIGS. 1 and 2, the current may be of the alternating, direct, or waveform type.

Referring now to FIG. 3, the electronic control device 50 for use with the electro-stimulator of FIGS. 1 and 2 includes a regulated power source 52, such as a battery and regulator, a stimulation timer circuit 54, a destimulation timer circuit 55, a stimulation power amplifier 56, and a destimulation power amplifier 57. The timer circuits and power amplifiers can be chosen from any of several well-known timers and amplifiers that can incorporate the dials 16, 18, 20, and 22. These dials may be of the variable resistive, capacitive, or pulse type to vary the timer frequency and power dissipation. Alternatively, input from the keys 44 stored in a microprocessor 60 (shown in dashed line) in the FIG. 2 embodiment can be used to vary the amplification and duration of the applied electrical current. The stimulation switch 24 and stimulation foot switch 32 on pedal assembly 30 are connected in parallel such that actuation of one or the other switch begins heart stimulation. Likewise, the destimulation switch 26 and stimulation foot switch 34 on pedal assembly 30 are connected in parallel such that the actuation of one or the other switch begins heart destimulation. Preferably, the switches are of the single-shot type that permit current to flow through the circuit for the amount of time set by the timers 54, 56, even when the switches are released. Alternatively, the switches may be of the type requiring manual positioning between the open and closed positions. In this alternative embodiment, the timers 54, 56 may provide an audible signal to indicate when the appropriate duration of electrical current application has been reached. The timers 54, 56 may also be eliminated. In this instance, the appropriate switch is manually closed until the surgeon visually observes that the heart has been properly stimulated or destimulated.

With reference now to FIG. 4, the electrode 37 is connected to the sinoatrial region 72 of heart 70 while the electrode 38 is connected to the atrioventricular region 74 in a unipolar arrangement, while the electrodes 43A, 43B are connected to the phrenic nerve (not shown) or to other regions of the body or heart. The separate connection regions on the heart serve to alternatively stimulate and destimulate the heart. The electrode terminations may be of the type used in pacemakers, such as corkscrews, clips, pads, tines or barbs, needles, etc. The electrodes 37, 38 may both be connected to the ventricular wall as shown in FIG. 5 in a bipolar arrangement or at any position that a pacemaker is commonly connected to. The electrodes 43A, 43B may be connected in a bipolar arrangement to the vagus nerve or one of its cardiac branches. In the bipolar arrangement, the electrodes 37, 38 are placed near each other at a particular region for stimulating the heart while the electrodes 43A, 45A are placed near each other at a second region for destimulating the heart. The tissue between each pair of serves to close the circuit such that electrical current from the power source and amplifier passes through the tissue to cause stimulation or destimulation of the heart.

When the electrodes are connected to other locations besides the heart, a series of current pulses is passed long enough through the tissue to augment any recurring natural heartbeat stimuli to stop the heart from beating. It has been found that a continuous pulse train for 10-30 seconds using a constant current of 10-1OO mA in conjunction with a constant pulse width of 0.01-0.5 msec. and a frequency between 6 Hz and 50 Hz applied to the epicardial parasympathetic nerves is sufficient to augment the recurring natural heartbeat stimuli to stop the heart. When the electrodes are connected directly to the heart, it is preferred that a burst pulse width of current be applied instead of a continuous pulse train. Once activity from the heart is sensed, a burst pulse width having the same current amplitude and frequency as in the constant pulse width is applied during the repolarization phase. Typically, the burst pulse time will be less than the continuous pulse train to stop the heart. Preferably, the burst pulse is programmable for different burst times, current amplitudes, and frequency. Upon cessation of heart destimulation, the natural heart beat stimuli will typically occur again automatically a short time thereafter. The separate heart stimulation leads, therefore, provide an added safety feature in the event that the heart does not automatically restart. In order to stimulate the heart, if required, a series of current pulses are passed through the tissue to initiate the natural heartbeat stimuli. These current pulses are similar to those used in pacemakers.

In use, the electrodes 37, 38 are secured at an appropriate position on the patient 80 (FIG. 6). During open surgery or minimally invasive surgery, as the surgeon 82 performs various steps such as cutting, stitching, etc., one of the foot switches 32, 34 is pressed to initiate or stop the heartbeat as required. For example, the surgeon may wish to stop the heartbeat while making one or a plurality of stitches where movement of the heart would normally be a hindrance. The heart may then be stimulated either naturally or artificially through the present device to beat for a predetermined time to permit blood flow throughout the body and then be destimulated or stopped again to continue stitching. If desired, the electrodes 43A, 45A may be connected to the phrenic nerve and/or the connector 49 may be attached to a respirator to still the lungs during the surgical procedure. When the electrodes are attached to the phrenic nerve, a continuous pulse train having the range of values as discussed previously is sufficient for controlling lung movement.

Referring now to FIG. 7, and according to a further embodiment, a set of four electrodes 102, 104, 106, and 108 are equally circumferentially spaced around a catheter 100. Each electrode 102-108 is embedded in and extends from an inner wall 110 to an outer wall 112 of the catheter 100. A separate insulated lead 102a, 104a, 106a, and 108a are each soldered or otherwise electrically connected to their respective electrode. The insulated leads extend through the catheter 100 and into the electronic control device 50. Any pair of electrodes can be accessed through extra switches in the control device 50 for supplying electrical current to the heart during stimulation and destimulation.

Referring now to FIG. 8, and according to a further embodiment, a set of three electrodes 122, 124 and 126 are equally circumferentially spaced around a catheter 120. Each electrode 122-126 is embedded in and extends from an inner wall 130 to an outer wall 132 of the catheter 120. A separate insulated lead 122a, 124a and 126a are each soldered or otherwise electrically connected to their respective electrode. As in the previous embodiment, the insulated leads extend through the catheter 100 and into the electronic control device 50. Any pair of electrodes can be accessed through extra switches in the control device 50 for supplying electrical current to the heart during stimulation and destimulation.

Although the catheters 100, 120 have been described with three or four electrodes, any number of electrodes may be provided, depending on the particular nerve stimulation application. For example, as shown in FIG. 9, two electrodes 142, 144 may be spaced axially on a catheter 140. The longitudinal centerline of each electrode 142, 144 extends perpendicularly to the axis of the catheter 140.

In FIG. 10, two electrodes 152, 154 are spaced axially and circumferentially from each other on the catheter 150. Their longitudinal centerlines extend parallel to the axis of the catheter. Two additional electrodes 156, 158 (shown in dashed line) may be provided on an opposite side of the catheter 150, as shown in FIG. 11.

In yet another embodiment, as shown in FIG. 12, a first electrode 162 is spaced axially and circumferentially from a pair of circumferentially electrodes 164, 166 on a catheter 160. Each of the electrodes 162-166 extends approximately 120°C around the circumference of the catheter 160.

The catheters 100-160 as shown in FIGS. 7-12 are preferably of a small size to fit easily into the internal jugular vein, superior vena cava or other appropriate vessel adjacent to the desired nerve bundle. The internal jugular vein is next to the vagal nerve bundle, and thus presents an ideal path for the catheter when attempting to stimulate the vagal nerve. The human internal jugular vein is about 2 to 6 mm in diameter and tapers over an estimated length of about 15 cm. Hence, the use of a 7F or smaller size catheter is contemplated. The electrodes are placed on the catheter in such a way that the amplitude required to stimulate the nerve fibers would have the correct field distribution. For an internal jugular vein of about 5 mm in diameter and a vagal nerve bundle of about 3 mm in diameter, and for an applied current of 10 mA with a frequency of 2-20 Hz, the spacing between the electrodes would need to be about 1-2 cm to achieve nerve stimulation. This spacing may vary depending on the size of the internal jugular vein and vagal nerve bundle, as well as the amount of applied current.

Referring now to FIG. 13, electrodes 104, 106 of the catheter 100 are in contact with a nerve (not shown) and have been selected to apply a current thereto. The circumferential current density through the nerve tissue, as represented by lines 170, diminishes as the distance increases from the pair of activated electrodes. FIG. 14 shows a similar occurrence for the three-electrode embodiment of FIG. 8. Since the electrodes in this embodiment are spaced a greater distance than the electrodes from in the FIG. 7 embodiment, the current distribution is not as concentrated, and therefore produces a different neural stimulation.

An axial current distribution may be required in addition to or in place of the circumferential distribution, as shown in FIG. 15, depending on the particular nerve stimulation desired. The axial current distribution is obtained by accessing a pair of axially spaced electrodes (FIG. 9) or a pair of axially and circumferentially spaced electrodes (FIGS. 10-12).

The preferred use of the electro-stimulation device would be a transvenous implementation through standard transvenous implantation techniques such as those used to implant pace/sense leads into the heart. For the method of transvenous vagal stimulation in laproscopic/endoscopic/minithorascopic surgical coronary artery bypass graft (CABG) procedures, the use of vagal nerve stimulation provides a reversible, quick acting (like an on/off switch) method for slowing the heart rate.

Although the foregoing description relates to the stimulation/destimulation of the heart during surgical procedures, it is not intended that the invention be limited thereto. The electro-stimulation device could be provided with two or more electrode-wielding catheters for use in multiple transvenous regions for the stimulation of different nerves. For example, a pair of catheters could be inserted into the internal jugular vein for stimulation of the right and left vagal nerve bundles. The right bundle could be used to elicit more specific heart effects and reduce heart rate and increase AV delay for antiarrhythmic and hemodynamic benefits; whereas the left bundle could be used to effect afferent vagal information and potentially reduce epileptic activity. An electrode-wielding catheter could be inserted into the very high internal jugular vein to stimulate the hypoglossal nerve and/or into the very low internal jugular vein or superior vena cava to stimulate the phrenic nerve for respiratory control. The stimulation of the phrenic nerve in conjunction with heart stimulation would insure that the blood is properly oxygenated during surgical procedures on the heart with intermittent heart destimulation. Likewise, catheters of the present invention could be inserted into the azygos or accessory hemizygous veins to stimulate the sympathetic nerves for increasing heart rate or altering DFT efficacy for antiarrhythmic and hemodynamic benefits. Other transvenous routes to nerve stimulation for functional purposes may also be applicable.

The electro-stimulation device may also have specificity for direction of neural stimulation in regards to the location of the vessel and the nerve bundle that is to be stimulated. For example, the phrenic nerve could be elicited on and off by a mere rotation of the transvenous catheter, depending on the location of the electrodes on the catheter and the resulting electric current density generated. In order to observe and control the amount of catheter rotation, a series of degree markings may be located on an outer circumference of the catheter at a position readily observable by the surgeon. Alternatively, the catheter may be associated with a rotary encoder to obtain a digital read-out of the amount of catheter rotation.

The electrodes of the intravenous catheters according to the present invention could also be used to manipulate the heart rate or hemodynamics in response to device sensors. In addition, in response to precursors of an arrhythmic event, the device may stimulate either the sympathetic or the parasympathetic individually or in combination to attempt to delay or prevent the event. Alternatively, current may be applied to different pairs of electrodes as discussed above.

Although the use of catheters having electrodes permanently mounted thereto for temporarily manipulating or stimulating nerves accessible through blood carrying vessels, it is to be understood that a more permanent nerve stimulation arrangement is possible by fixing electrodes onto the inside of the vessel adjacent to the nerve to be stimulated. Thus, this new device in its preferred embodiment eliminates the potential for direct nerve damage and reduces the invasiveness of the placement of the electrodes for direct neural stimulation in conjunction with implantable medical devices. Examples of how the present invention may be employed in the context of implantable medical devices are illustrated in FIGS. 16-19.

FIG. 16 illustrates an embodiment of the present invention employing a permanently implantable cardiac pacemaker 300 coupled to an electrode lead 304 used to stimulate the vagal nerve in accordance with the present invention. The pacemaker is also provided with a second electrical lead 308, which, like electrical lead 304 is coupled to the circuitry within the housing of pacemaker 300 by means of a connector block 302. Pacemaker 300 includes therein both a dual chamber cardiac pacemaker and an implantable nerve stimulator, and may correspond to that illustrated in U.S. Pat. No. 5,334,221 issued to Bardy; U.S. Pat. No. 5,330,507 issued to Schwartz or U.S. Pat. No. 5,199,428 issued to Obel et al, all of which are incorporated herein by reference in their entireties.

Electrode lead 304 has an array of electrodes as illustrated in FIGS. 7-15, discussed above, located at or adjacent its distal end 306 which is positioned within the internal jugular vein 316, with electrodes chosen to direct the stimulation pulses provided by the electrodes to the vagal nerve in order to slow heart rate. The second electrode lead 308 carries a pair or electrodes 310 for sensing depolarizations of the atrium of the patient's heart and a pair of electrodes 312 for sensing and pacing the ventricle of the patient's heart. As described in the above cited patents, the electrodes on lead 304 may be employed to slow the patients heart rhythm in order to prevent or treat detected arrhythmias, ischemia, angina or other problems. The electrodes 310 and 312 may by employed to sense the rate of the heart and to ensure that the heart is beating at an adequate rate, preventing over-stimulation of the vagal nerve from causing the heart to drop below a base heart rate determined either as a fixed parameter or as a function of an indwelling activity sensor within pacemaker 300. Electrode lead 304 may be formed with a bend 318, preformed into the body of the lead a distance from the electrode array the distal end of the lead 306 to position it appropriately for vagal nerve stimulation. The lead may be inserted and positioned generally according to the procedure disclosed in U.S. Pat. No. 5,354,318 issued to Taepke, describing a similarly located and configured lead, also incorporated herein by reference in its entirety.

FIG. 17 illustrates an embodiment of the invention in which an implanted stimulator 400 is used in conjunction with an electrode lead according to the present invention to stimulate the hypoglossal nerve to treat obstructive sleep apnea. The pulse generator may correspond to that disclosed in U.S. Pat. No. 5,549,655 issued to Erickson and incorporated herein by reference in its entirety. The stimulator 400 is provided with a first electrode lead 404 which carries adjacent its distal end 406 an array of electrodes as described in FIGS. 7-15, discussed above. The lead is located relatively higher up within the internal jugular artery than the electrode array in FIG. 16 and is directed to stimulate the hypoglossal nerve by selection of appropriate electrodes as described above. Like the lead 304 described in FIG. 16, lead 404 may optionally be provided with a preformed bend 414, an appropriate distance from the location of the electrode array the distal end 406 of the catheter to position it in appropriate position and orientation to stimulate the hypoglossal nerve. The lead, like lead 304 in FIG. 16, may be inserted according to the procedure described in U.S. Pat. No. 5,354,318 issued to Taepke. The pulse generator 400 is additionally provided with a second lead 408 which carries a pressure sensor 410 which is used to synchronize delivery of hypoglossal nerve stimulus pulses to the detected inspiratory phase of the respiration cycle as described in the above cited Erickson patent.

FIG. 18 illustrates an additional embodiment of the present invention including a pulse generator 500 employed to stimulate the phrenic nerve in order to provide a diaphragmatic pacer. Pacer 500 may correspond generally to that disclosed in U.S. Pat. No. 5,056,519, issued to Vince et al. which employs a signal indicative of the normal respirative function of the right diaphragm to regulate stimulation of the left phrenic nerve to correspondingly stimulate the left diaphragm. A pulse generator 500 is provided with a second lead 508 which carries at its distal tip a temperature sensor 510 which is employed to sense the temperature changes within body tissues resulting from inspiration of outside air through the upper airways. Temperature sensor 510 may be located within the airway to the right diaphragm as described in the Vince patent and employed to regulate stimulus pulses provided to the electrodes on lead 504 so that the left diaphragm functions in synchrony with the inspiratory cycle of the right diaphragm. Lead 504 may be provided with a preformed bend 514 located an appropriate distance from the electrode array located at the distal end of 506 of the lead to position the electrode array adjacent the phrenic nerve. The lead may be introduced using the procedure described in the above cited Gunderson patent.

FIG. 19 illustrates an embodiment of the invention employed in conjunction with an implantable cardioverter/defibrillator 600 which employs vagal nerve stimulation as an adjunct to its array of antitachyarrhythmia therapies including antitachyacardia pacing, cardioversion and defibrillation. Pulse generator 600 may correspond, for example, to the pulse generator illustrated in U.S. Pat. No. 5,014,698 issued to Collins or U.S. Pat. No. 5,243,980 issued to Mehra, both incorporated herein by reference in their entireties.

Pulse generator 600 is provided with an electrical lead 604 which carries adjacent its distal end 606 an array of electrodes as described in conjunction with FIGS. 7-14 above. Electrode lead 604 may correspond to electrode lead 304 illustrated in FIG. 15, with its distal end 606 located within the internal jugular vein in a position appropriate to stimulate the vagal nerve. The pulse generator 600 is also provided with a second electrode lead 608 which carries first and second defibrillation electrodes 610 and 612 and pacing/sensing electrodes 614 and 616 which are employed to sense and pace the ventricle of the patient's heart The vagal nerve stimulator may be employed in conjunction with delivery of therapies of treatment of arrhythmias or prevention of arrhythmias as described in the above cited Collins et al patent or may be employed as part of a diagnostic regimen as described in the above cited Mehra patent.

The embodiments of the invention illustrated in FIGS. 16-19 above are intended to be exemplary of general types of devices in which the present invention may be employed by transvenously located an electrode or array of electrodes in a blood vessel adjacent a desired nerve to be stimulated, as discussed above. It should be understood that permanently implanted leads configured and located according to the present invention may be used with a wide variety of implantable electrical devices not specifically illustrated in conjunction with FIGS. 16-19, including implantable drug dispensers, implantable muscle or nerve stimulators, and implantable monitoring systems in which regulation of one or more nervous functions is desired. It should also be understood that in conjunction with such devices, as discussed above, electrodes may be located bi-laterally, and employed to stimulate the same or different nerves, also as discussed above.

Reasonable variation and modification are possible within the spirit of the foregoing specification and drawings without departing from the scope of the invention.

Jonkman, Kenneth R., Hill, Michael R. S.

Patent Priority Assignee Title
10080896, Mar 15 2013 CIRTEC MEDICAL CORP Implantable pulse generator that generates spinal cord stimulation signals for a human body
10166395, May 23 2000 The Feinstein Institutes for Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
10172549, Mar 09 2016 Cardionomic, Inc. Methods of facilitating positioning of electrodes
10188343, Mar 09 2016 Cardionomic, Inc. Methods of monitoring effects of neurostimulation
10207112, Apr 29 2010 Medtronic, Inc. Cardiac therapy including vagal stimulation
10220203, Jun 09 2009 SetPoint Medical Corporation Nerve cuff with pocket for leadless stimulator
10226628, Mar 15 2013 CIRTEC MEDICAL CORP Implantable pulse generator that generates spinal cord stimulation signals for a human body
10258736, May 17 2012 Tandem Diabetes Care, Inc. Systems including vial adapter for fluid transfer
10265526, Mar 15 2013 CIRTEC MEDICAL CORP Spinal cord stimulator system
10314501, Jan 20 2016 SetPoint Medical Corporation Implantable microstimulators and inductive charging systems
10335280, Jan 19 2000 Medtronic, Inc. Method for ablating target tissue of a patient
10335597, Mar 15 2013 CIRTEC MEDICAL CORP Spinal cord stimulator system
10384068, Dec 23 2009 SetPoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
10413730, Mar 15 2013 CIRTEC MEDICAL CORP Implantable pulse generator that generates spinal cord stimulation signals for a human body
10448884, Mar 09 2016 Cardionomic, Inc. Methods of reducing duty cycle during neurostimulation treatment
10449358, Mar 26 2012 SetPoint Medical Corporation Devices and methods for modulation of bone erosion
10493278, Jan 05 2015 CARDIONOMIC, INC Cardiac modulation facilitation methods and systems
10532215, Jan 25 2016 SetPoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
10549101, Apr 25 2005 Cardiac Pacemakers, Inc. Method and apparatus for pacing during revascularization
10561846, May 23 2000 The Feinstein Institutes for Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
10576273, May 22 2014 Cardionomic, Inc. Catheter and catheter system for electrical neuromodulation
10583291, Mar 15 2013 CIRTEC MEDICAL CORP Implantable pulse generator that generates spinal cord stimulation signals for a human body
10583304, Jan 25 2016 SetPoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
10589130, May 25 2006 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
10596367, Jan 13 2016 SetPoint Medical Corporation Systems and methods for establishing a nerve block
10695569, Jan 20 2016 SetPoint Medical Corporation Control of vagal stimulation
10716936, Jun 09 2009 SetPoint Medical Corporation Nerve cuff with pocket for leadless stimulator
10722716, Sep 08 2014 Cardionomia Inc. Methods for electrical neuromodulation of the heart
10894160, Sep 08 2014 Cardionomic, Inc. Catheter and electrode systems for electrical neuromodulation
10905873, Dec 06 2006 The Cleveland Clinic Foundation Methods and systems for treating acute heart failure by neuromodulation
10912712, Mar 25 2004 The Feinstein Institutes for Medical Research Treatment of bleeding by non-invasive stimulation
10952665, Mar 09 2016 Cardionomic, Inc. Methods of positioning neurostimulation devices
11051744, Apr 10 2013 SetPoint Medical Corporation Closed-loop vagus nerve stimulation
11077298, Aug 13 2018 Cardionomic, Inc. Partially woven expandable members
11110287, Dec 23 2009 SetPoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
11129988, Apr 29 2010 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
11135362, Jul 30 2009 Tandem Diabetes Care, Inc. Infusion pump systems and methods
11173307, Aug 14 2017 SetPoint Medical Corporation Vagus nerve stimulation pre-screening test
11207518, Dec 27 2004 The Feinstein Institutes for Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
11229398, Mar 09 2016 Cardionomic, Inc. Electrode assemblies for neurostimulation treatment
11260229, Sep 25 2018 The Feinstein Institutes for Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
11278718, Jan 13 2016 SetPoint Medical Corporation Systems and methods for establishing a nerve block
11285263, Jul 30 2009 Tandem Diabetes Care, Inc. Infusion pump systems and methods
11311725, Oct 24 2014 SetPoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
11344724, Dec 27 2004 The Feinstein Institutes for Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
11383091, Jan 25 2016 SetPoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
11406833, Feb 03 2015 SetPoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
11471681, Jan 20 2016 SetPoint Medical Corporation Batteryless implantable microstimulators
11547852, Jan 20 2016 SetPoint Medical Corporation Control of vagal stimulation
11559687, Sep 13 2017 Cardionomic, Inc. Methods for detecting catheter movement
11607176, May 06 2019 Cardionomic, Inc. Systems and methods for denoising physiological signals during electrical neuromodulation
11648395, Aug 13 2018 Cardionomic, Inc. Electrode assemblies for neuromodulation
11806159, Mar 09 2016 Cardionomic, Inc. Differential on and off durations for neurostimulation devices and methods
11857788, Sep 25 2018 The Feinstein Institutes for Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
11890471, Aug 14 2017 SetPoint Medical Corporation Vagus nerve stimulation pre-screening test
7142910, Aug 26 1997 Emory University Methods of indirectly stimulating the vagus nerve with an electrical field
7184828, Sep 26 2000 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
7184829, Apr 30 1996 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
7225019, Apr 30 1996 Medtronic, Inc Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
7245967, Jun 12 2002 Pacesetter, Inc Parasympathetic nerve stimulation for termination of supraventricular arrhythmias
7269457, Apr 30 1996 Medtronic, Inc Method and system for vagal nerve stimulation with multi-site cardiac pacing
7310552, Aug 26 1997 Apparatus for indirectly stimulating the vagus nerve with an electrical field
7340299, Aug 26 1997 Methods of indirectly stimulating the vagus nerve to achieve controlled asystole
7403819, Jun 12 2002 Pacesetter, Inc Parasympathetic nerve stimulation for control of AV conduction
7615015, Jan 19 2000 Medtronic, Inc. Focused ultrasound ablation devices having selectively actuatable emitting elements and methods of using the same
7657312, Nov 03 2003 Cardiac Pacemakers, Inc Multi-site ventricular pacing therapy with parasympathetic stimulation
7706882, Jan 19 2000 Medtronic, Inc Methods of using high intensity focused ultrasound to form an ablated tissue area
7840278, Jun 25 1999 Devices and methods for vagus nerve stimulation
7869881, Dec 24 2003 Cardiac Pacemakers, Inc Baroreflex stimulator with integrated pressure sensor
7917230, Jan 30 2007 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
7925352, Mar 27 2009 NuXcel2, LLC System and method for transvascularly stimulating contents of the carotid sheath
7949409, Jan 30 2007 Cardiac Pacemakers, Inc. Dual spiral lead configurations
8024050, Dec 24 2003 Cardiac Pacemakers, Inc Lead for stimulating the baroreceptors in the pulmonary artery
8036741, Apr 30 1996 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
8116883, Jun 04 2003 NuXcel2, LLC Intravascular device for neuromodulation
8126560, Dec 24 2003 Cardiac Pacemakers, Inc Stimulation lead for stimulating the baroreceptors in the pulmonary artery
8170668, Jul 14 2006 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
8200331, Nov 04 2004 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
8200332, Nov 04 2004 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
8221402, Jan 19 2000 Medtronic, Inc Method for guiding a medical device
8224438, Jul 21 1997 BHL PATENT HOLDINGS LLC Method for directed intranasal administration of a composition
8244378, Jan 30 2007 Cardiac Pacemakers, Inc. Spiral configurations for intravascular lead stability
8287495, Jul 30 2009 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
8298184, Jul 30 2009 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
8311647, Jan 30 2007 Cardiac Pacemakers, Inc. Direct delivery system for transvascular lead
8369954, Mar 27 2008 NuXcel2, LLC System and method for transvascularly stimulating contents of the carotid sheath
8391970, Aug 27 2007 The Feinstein Institutes for Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
8406868, Apr 29 2010 Medtronic, Inc.; Medtronic, Inc Therapy using perturbation and effect of physiological systems
8408421, Sep 16 2008 TANDEM DIABETES CARE, INC Flow regulating stopcocks and related methods
8412336, Dec 29 2008 Realeve, LLC Integrated delivery and visualization tool for a neuromodulation system
8412338, Nov 18 2008 SetPoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
8412350, Jan 30 2007 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
8423134, Apr 29 2010 Medtronic, Inc.; Medtronic, Inc Therapy using perturbation and effect of physiological systems
8448824, Sep 16 2008 TANDEM DIABETES CARE, INC Slideable flow metering devices and related methods
8457746, Dec 24 2003 Cardiac Pacemakers, Inc. Implantable systems and devices for providing cardiac defibrillation and apnea therapy
8473062, May 01 2008 Realeve, LLC Method and device for the treatment of headache
8473076, Dec 24 2003 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
8494641, Apr 22 2009 Realeve, LLC Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
8571655, Nov 03 2003 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
8612002, Dec 23 2009 SetPoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
8620425, Apr 29 2010 Medtronic, Inc Nerve signal differentiation in cardiac therapy
8626301, Dec 24 2003 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
8639327, Apr 29 2010 Medtronic, Inc Nerve signal differentiation in cardiac therapy
8650937, Sep 19 2008 TANDEM DIABETES CARE, INC Solute concentration measurement device and related methods
8706223, Jan 19 2011 Medtronic, Inc.; Medtronic, Inc Preventative vagal stimulation
8718763, Jan 19 2011 Medtronic, Inc.; Medtronic, Inc Vagal stimulation
8725259, Jan 19 2011 Medtronic, Inc.; Medtronic, Inc Vagal stimulation
8729129, Mar 25 2004 The Feinstein Institutes for Medical Research Neural tourniquet
8758323, Jul 30 2009 TANDEM DIABETES CARE, INC Infusion pump system with disposable cartridge having pressure venting and pressure feedback
8768462, Nov 04 2004 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
8781574, Dec 29 2008 Realeve, LLC Integrated delivery and visualization tool for a neuromodulation system
8781578, Nov 14 2008 Cardiac Pacemakers, Inc Mass attribute detection through phrenic stimulation
8781582, Jan 19 2011 Medtronic, Inc.; Medtronic, Inc Vagal stimulation
8781583, Jan 19 2011 Medtronic, Inc. Vagal stimulation
8788034, May 09 2011 SetPoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
8855767, Dec 23 2009 SetPoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
8886325, Apr 22 2009 Realeve, LLC Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
8886339, Jun 09 2009 SetPoint Medical Corporation Nerve cuff with pocket for leadless stimulator
8888699, Apr 29 2010 Medtronic, Inc.; Medtronic, Inc Therapy using perturbation and effect of physiological systems
8914114, May 23 2000 The Feinstein Institutes for Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
8926561, Jul 30 2009 TANDEM DIABETES CARE, INC Infusion pump system with disposable cartridge having pressure venting and pressure feedback
8986253, Jan 25 2008 TANDEM DIABETES CARE, INC Two chamber pumps and related methods
8996116, Oct 30 2009 SetPoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
9108057, May 04 2004 The Cleveland Clinic Foundation Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system
9155893, Jan 19 2011 Medtronic, Inc. Use of preventative vagal stimulation in treatment of acute myocardial infarction or ischemia
9162064, Dec 23 2009 SetPoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
9174041, Jun 09 2009 SetPoint Medical Corporation Nerve cuff with pocket for leadless stimulator
9199085, Apr 25 2005 Cardiac Pacemakers, Inc. Method and apparatus for pacing during revascularization
9211377, Jul 30 2009 TANDEM DIABETES CARE, INC Infusion pump system with disposable cartridge having pressure venting and pressure feedback
9211409, Mar 31 2008 The Feinstein Institutes for Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
9211410, May 09 2011 SetPoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
9211413, Jan 19 2011 Medtronic, Inc. Preventing use of vagal stimulation parameters
9227088, May 25 2006 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
9320908, Jan 15 2009 Realeve, LLC Approval per use implanted neurostimulator
9381349, Jul 21 1997 AUTONOMIC TECHNOLOGIES, INC Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation
9415225, Apr 25 2005 Cardiac Pacemakers, Inc. Method and apparatus for pacing during revascularization
9468764, Apr 29 2010 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
9480790, Dec 06 2006 The Cleveland Clinic Foundation Methods and systems for treating acute heart failure by neuromodulation
9533159, Aug 30 2013 Tijee Corporation Unwanted stimulation detection during cardiac pacing
9554694, Dec 29 2008 Realeve, LLC Integrated delivery and visualization tool for a neuromodulation system
9555186, Jun 05 2012 TANDEM DIABETES CARE, INC Infusion pump system with disposable cartridge having pressure venting and pressure feedback
9572983, Mar 26 2012 SetPoint Medical Corporation Devices and methods for modulation of bone erosion
9604065, Aug 30 2013 Cardiac Pacemakers, Inc. Unwanted stimulation detection during cardiac pacing
9649495, Apr 25 2005 Cardiac Pacemakers, Inc. Method and apparatus for pacing during revascularization
9662490, Mar 31 2008 The Feinstein Institutes for Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
9700716, Jun 09 2009 SetPoint Medical Corporation Nerve cuff with pocket for leadless stimulator
9724119, May 25 2006 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
9795790, Aug 30 2013 Cardiac Pacemakers, Inc. Unwanted stimulation detection during cardiac pacing
9833621, Sep 23 2011 SetPoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
9849286, May 09 2011 SetPoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
9878150, Dec 06 2006 The Cleveland Clinic Foundation Methods and systems for increasing heart contractility by neuromodulation
9931134, May 25 2006 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
9962486, Mar 14 2013 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
9987492, May 23 2000 The Feinstein Institutes for Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
9993651, Dec 23 2009 SetPoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
Patent Priority Assignee Title
5014698, Oct 06 1987 Medtronic, Inc Method of and system for monitoring and treating a malfunctioning heart
5044367, Jun 26 1989 The State of Oregon Acting by and Through the State Board of Higher Method and apparatus for switching cardiac stimulation signals
5056519, May 14 1990 Unilateral diaphragmatic pacer
5199428, Mar 22 1991 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
5203326, Dec 18 1991 Pacesetter, Inc Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
5243980, Jun 30 1992 Medtronic, Inc. Method and apparatus for discrimination of ventricular and supraventricular tachycardia
5330507, Apr 24 1992 Medtronic, Inc. Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias
5334221, Jun 30 1992 Medtronic, Inc. Method and apparatus for treatment of angina same
5354318, Apr 30 1993 Medtronic, Inc.; DUTHLER, REED A Method and apparatus for monitoring brain hemodynamics
5356425, Jun 30 1992 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation and flutter
5501703, Jan 24 1994 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
5507784, Sep 23 1993 Medtronic, Inc. Method and apparatus for control of A-V interval
5549655, Sep 21 1994 INSPIRE MEDICAL SYSTEMS, INC Method and apparatus for synchronized treatment of obstructive sleep apnea
5578061, Oct 03 1995 Pacesetter AB Method and apparatus for cardiac therapy by stimulation of a physiological representative of the parasympathetic nervous system
5651378, Feb 20 1996 Maquet Cardiovascular, LLC Method of using vagal nerve stimulation in surgery
5690681, Mar 29 1996 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
5700282, Oct 13 1995 Heart rhythm stabilization using a neurocybernetic prosthesis
5792187, Feb 22 1993 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
5913876, Feb 20 1996 Maquet Cardiovascular, LLC Method and apparatus for using vagus nerve stimulation in surgery
5964789, Dec 24 1992 Transcutaneous electric muscle/nerve controller/feedback unit
6073048, Nov 17 1995 Medtronic, Inc Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
//
Executed onAssignorAssigneeConveyanceFrameReelDoc
Nov 15 2001Medtronic, Inc.(assignment on the face of the patent)
Oct 23 2020AFERO INC VENTURE LENDING & LEASING IX, INC SECURITY INTEREST SEE DOCUMENT FOR DETAILS 0542560299 pdf
Date Maintenance Fee Events
Jul 21 2004ASPN: Payor Number Assigned.
Dec 27 2004M1551: Payment of Maintenance Fee, 4th Year, Large Entity.
Dec 19 2008M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Oct 02 2012M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Nov 23 20074 years fee payment window open
May 23 20086 months grace period start (w surcharge)
Nov 23 2008patent expiry (for year 4)
Nov 23 20102 years to revive unintentionally abandoned end. (for year 4)
Nov 23 20118 years fee payment window open
May 23 20126 months grace period start (w surcharge)
Nov 23 2012patent expiry (for year 8)
Nov 23 20142 years to revive unintentionally abandoned end. (for year 8)
Nov 23 201512 years fee payment window open
May 23 20166 months grace period start (w surcharge)
Nov 23 2016patent expiry (for year 12)
Nov 23 20182 years to revive unintentionally abandoned end. (for year 12)